Upadacitinib
CAS No. : 1310726-60-3
(Synonyms: ABT-494)
| Size | Price | Stock |
|---|---|---|
| 5mg | $110 | In-stock |
| 10mg | $160 | In-stock |
| 25mg | $280 | In-stock |
| 50mg | $390 | In-stock |
| 100mg | $550 | In-stock |
| 200mg | $850 | In-stock |
| 500mg | $1360 | In-stock |
| 1g | $2300 | In-stock |
| 5 g | Get quote | |
| 10 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-19569 |
| M.Wt: | 380.37 |
| Formula: | C17H19F3N6O |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research[1][2]. IC50 & Target:IC50: 43 nM (JAK1), 200 nM (JAK2)[1] In Vitro:In biochemical assays, Upadacitinib is 74-fold more selective for JAK-1 than for JAK-2 (which is involved in erythropoiesis) and 58-fold more selective for JAK-1 than for JAK-3 (which is involved in immunosurveillance)[1]. The enhanced selectivity of Upadacitinib for JAK-1 over JAK-2 and JAK-3 may offer an improved benefit–risk profile in patients with RA range[2]. In Vivo:Upadacitinib (0.1-10 mg/kg; oral gavage; twice a day for 10 days) demonstrates efficacy in rat arthritis models[3].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Upadacitinib
- Cat. No.:
- HY-19569
- Quantity:
Your information is safe with us.